| 초록 |
Nitric oxide (NO) has been known to play important roles in the control of tumor progression. Recent researches have shown the potential of NO in a direct use as an apoptotic agent or in combination with chemotherapeutic agents to enhance its cytotoxicity for a variety of cancers. However, the direct delivery of NO into tumor cells is problematic, because NO has an extremely short half-life in the body. Herein, we selected S-nitrosoglutathione (GSNO) as an endogenous NO donor. GSNO was conjugated to the hyaluronic acid-graft-poly(L-lactide-co-glycolide) (HA-PLGA) copolymer. GSNO-conjugated HA nanoparticles (GSNO-HANPs) consists of the HA shells and the GSNO-conjugated PLGA core. The nanoparticle would enhance the stability of GSNO at an intracellular compartment. In contrast, the nanoparticles would degrade by hyaluronidases-1 (Hyal-1) at the cytosol of tumor cells. The GSNO from degraded nanoparticles can be reacted with reducing agent to generate NO at an intracellular compartment. |
